Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial

Objective In the SENSCIS trial in subjects with systemic sclerosis–associated interstitial lung disease (SSc‐ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categori...

Full description

Saved in:

Bibliographic Details
Published in:	Arthritis & rheumatology (Hoboken, N.J.) Vol. 73; no. 4; pp. 671 - 676
Main Authors:	Maher, Toby M., Mayes, Maureen D., Kreuter, Michael, Volkmann, Elizabeth R., Aringer, Martin, Castellvi, Ivan, Cutolo, Maurizio, Stock, Christian, Schoof, Nils, Alves, Margarida, Raghu, Ganesh
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01.04.2021 John Wiley and Sons Inc
Subjects:	Adult Aged Confidence intervals Death Disease Progression Double-Blind Method Double-blind studies Female Full Length Humans Indoles - pharmacology Indoles - therapeutic use Lung - drug effects Lung - physiopathology Lung diseases Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Lung Diseases, Interstitial - physiopathology Male Middle Aged Mortality Placebos Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Respiratory function Scleroderma Scleroderma, Systemic - complications Scleroderma, Systemic - physiopathology Systemic Sclerosis Treatment Outcome
ISSN:	2326-5191, 2326-5205, 2326-5205
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!